Elutia Valuation Multiples

Elutia Overview

About Elutia

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women’s Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Founded

2015

HQ

Employees

51

Website

aziyo.com

Sectors

Medical DevicesBioTechDeepTechFemTechHealthTech

Financials (LTM)

Revenue: $12M

EBITDA: ($13M)

EV

$19M

Valuation Multiples

Multiples.vc

Start free trial

Elutia Financials

Elutia reported last 12-month revenue of $12M and negative EBITDA of ($13M).

In the same LTM period, Elutia generated $7M in gross profit, ($13M) in EBITDA losses, and $31M in net income.

Elutia P&L

In the most recent fiscal year, Elutia reported revenue of $12M and EBITDA of ($13M).

Elutia expects next 12-month revenue of XXX and NTM EBITDA of XXX

Elutia Stock Performance

Elutia has current market cap of $51M, and enterprise value of $19M.

Elutia's stock price is $1.20.

Elutia Valuation Multiples

Elutia trades at 1.6x EV/Revenue multiple, and (1.5x) EV/EBITDA.

Elutia Financial Valuation Multiples

As of April 19, 2026, Elutia has market cap of $51M and EV of $19M.

Equity research analysts estimate Elutia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Elutia has a P/E ratio of 1.7x.

Elutia Margins & Growth Rates

Elutia's revenue in the last 12 month grew by 1%.

Elutia's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Elutia's rule of 40 is (110%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Elutia's rule of X is (113%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Elutia Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Elutia M&A Activity

Elutia acquired XXX companies to date.

Last acquisition by Elutia was on XXXXXXXX, XXXXX. Elutia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Elutia Investment Activity

Elutia invested in XXX companies to date.

Elutia made its latest investment on XXXXXXXX, XXXXX. Elutia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).